| Name | Title | Contact Details |
|---|---|---|
Michael Holmes |
Senior Vice President and Chief Technology Officer | Profile |
New Horizon Agency Group is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ReCode Therapeutics is a biopharmaceutical company developing precision medicines for pulmonary diseases with significant unmet medical need.
Actym Therapeutics has engineered a new drug modality harnessing the power of a genetically modified bacterial vehicle that safely introduces therapeutic payloads to activate the immune response in the tumor microenvironment. To achieve targeted anti-tumor effects, we have developed a systemically administered treatment that exploits intrinsic TME-specific metabolites, enabling selective enrichment of the bacterial vehicle in tumors. After cell-specific entry, our lead candidate, ACTM-838, positively activates tumor-resident myeloid cells and delivers two synergistic payloads, optimized IL-15 and STING, unlocking a comprehensive and durable innate and adaptive anti-tumor immune response. With the ability to tailor our platform utilizing a range of payload combinations, we aim to achieve a new level of therapeutic impact for cancer patients across multiple tumor types.
Ocugen Inc.is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19.
MaxCyte is a US-based global company dedicated to accelerating the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines.